Sample deliverable · market-entry report
Build a plant — or enter another way first?
A sample of our Stage 0 for a real Caspian/CIS market. Which market — shown on a call under NDA. Here: the method and the headline conclusion; the specifics (market, niches, partners, prices, regulatory route) come with the full sample.
The question we answered
The investor was weighing a full plant — an order of magnitude of $26–32M in capital expenditure. The real question was not 'how to build' but 'whether to, and what it yields'. Entering via imports first turns out to be several times cheaper in the early years — and that changes the whole decision.
What we examined (method)
The report is organised by market dimensions, not by 'attractive' hypotheses:
- The regulator and realistic registration timelines.
- Industrial parks and free economic zones — what's available to a new plant.
- Market size: how much is imported versus made locally.
- Local players and who holds registrations for foreign manufacturers.
- What actually sits on pharmacy shelves — with a price audit.
- Stress-testing the 'obvious' open niches — most, on checking, turned out saturated by imports.
- A phased recommendation and a separate 'what NOT to do'.
- Staged finances and a list of open questions needing field verification.
- One concrete next step.
The headline conclusion
Building a full plant now is premature. The right sequence: first enter the market by selling imported product under a local registration-holding partner (1–2 years), then decide on your own manufacturing from real demand. Cheaper, faster, and it removes the biggest risk — building the wrong thing.
A lesson that repeats
One player opened an office in this market without a local registration-holding partner — and failed. Another entered via a partner — and took hold. Entry structure drives the outcome more than the product itself. These are the patterns niche research surfaces.
How we separate fact from hypothesis
In the report we explicitly mark what a primary source confirms versus what needs on-the-ground field verification — we don't pass a guess off as fact. That's exactly why you can make a multi-million decision on such a report, not on optimism.
Full sample — on request
The full deliverable names the market, the specific assessed niches, local partners, real pharmacy prices and the exact regulatory route. We'll walk you through it on a call and scope the same study for your target market.
Request the full sample
Message on Telegram — we'll show the full report and discuss applying the method to your market.
The specific market, niches and partners are disclosed on a call under NDA. The report is a research-stage artifact; some data is marked as needing field verification.